President Donald Trump’s April 2026 executive order on accelerating treatments for serious mental illness does something the psychedelic industry has been waiting for, and quietly fearing. It removes ambiguity.
For years, psychedelic drug development has lived in a strange middle ground. Compelling early data. Strong patient demand. Growing investor interest. But a regulatory pathway that felt uncertain, slow, and at times philosophically conflicted. The new directive changes that tone. It pushes the U.S. Food and Drug Administration to prioritize review of certain psychedelic therapies, leans into Breakthrough Therapy designations, signals openness to faster scheduling decisions, and encourages expanded access pathways.
The message is simple. If the science is there, the government does not want to be the bottleneck.
Markets responded immediately. Psychedelic equities moved higher as investors recalibrated timelines. In biotech, time is valuation. Shorter paths to approval compress risk and expand upside. But the reaction also revealed something more subtle. Not all companies moved equally, and for good reason.
This order does not lift the entire sector. It sharpens it.
The companies closest to the finish line
The most immediate beneficiaries are those already aligned with the FDA’s preferred framework, meaning late-stage programs and Breakthrough Therapy designations.
Compass Pathways sits at the front of that group. Its COMP360 program in treatment-resistant depression has delivered positive Phase 3 data, and the company is moving toward regulatory submission. In a world where the FDA is being asked to move faster, Compass is not hypothetical. It is actionable.
Atai Life Sciences, through its AtaiBeckley collaboration, is advancing BPL-003, an intranasal 5-MeO-DMT therapy with Breakthrough designation. Its Phase 3 timeline now intersects directly with a more receptive regulatory environment.
Cybin, now operating as Helus Pharma, is also positioned to benefit. CYB003 has entered pivotal development with FDA support, giving it a credible path into the same accelerated lane.
MindMed, now Definium Therapeutics, broadens the field with its LSD-based MM120 program for anxiety. With multiple Phase 3 readouts expected, it represents a different category of opportunity, one aimed at larger, more traditional psychiatric indications.
GH Research completes the near-term cohort. After clearing a clinical hold, its 5-MeO-DMT program is back on track and approaching late-stage development.
These companies have something in common. They are not just telling a story. They are approaching a regulatory decision.
Creating front runners
What the market risks overlooking is that the executive order does not only accelerate approvals. It also changes how the next generation of psychedelic-inspired drugs will be valued.
That is where Enveric Biosciences enters the conversation.
Unlike the companies above, Enveric is not racing toward a near-term approval of a classic psychedelic. Its lead candidate, EB-003, is a non-hallucinogenic neuroplastogen derived from DMT. The goal is not to optimize the psychedelic experience. It is to remove it.
That distinction may become more important, not less, under a faster FDA framework.
The core challenge facing first-wave psychedelic therapies is not only regulatory approval. It is scalability. Treatments that require monitored sessions, specialized clinics, and hours of supervision create friction at every level, from reimbursement to infrastructure. Even if approved, they risk becoming constrained solutions to massive problems.
Enveric is building toward a different endpoint. A drug that engages neuroplasticity pathways without hallucinations has the potential to fit into conventional pharmaceutical models. Prescribable. Scalable. Repeatable. In other words, compatible with the system the FDA already knows how to regulate efficiently.
In a slower regulatory environment, that approach can be overshadowed by the urgency of getting any psychedelic therapy approved. In a faster one, the calculus shifts. Investors and strategics begin to look beyond first approvals toward second-generation dominance.
The recent $1.2 billion move by AbbVie into the space through its acquisition of Gilgamesh Pharmaceuticals assets was an early signal of that shift. Large pharma is not only interested in whether psychedelics work. It is interested in how they can be made to work at scale.
That is precisely the question Enveric is trying to answer.
A sector being split in real time
The executive order is best understood not as a rising tide, but as a sorting mechanism.
On one side are companies with late-stage, regulator-ready assets. They stand to benefit immediately from faster review timelines and clearer federal support.
On the other are companies building what comes after. Non-hallucinogenic compounds. Novel delivery mechanisms. Scalable treatment paradigms. Their value is less tied to the next FDA decision and more tied to what the market looks like five years after that decision.
Both groups matter. But they will be valued differently.
The real test begins now
There is a temptation to read this moment as validation. For the industry, it is closer to accountability.
The FDA has already shown, through past decisions, that it will not lower its standards for psychedelic therapies. Questions around trial design, durability of effect, and functional unblinding remain unresolved. Faster pathways do not remove those questions. They compress the time available to answer them.
For companies like Compass, Atai, Cybin, MindMed, and GH Research, the task is immediate. Convert momentum into approvals.
For Enveric, the task is more strategic. Prove that the next generation of neuroplastogenic drugs can deliver the same therapeutic benefit without the operational constraints that define the first wave.
The executive order does not decide who wins. It simply ensures that we will find out sooner.
And in this sector, sooner changes everything.